Trial Profile
Phase II trial of neoadjuvant docetaxel and ZD 1839 (Iressa) [gefitinib] followed by radical prostatectomy in patients with high risk, locally advanced prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gefitinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 06 Feb 2012 Actual end date 1 Nov 2007 added as reported by ClinicalTrials.gov.
- 25 Jul 2006 Status change
- 28 Dec 2005 New trial record.